In general all small bowel adenocarcinomas have similar biological behavior irrespective of anatomical site, except that localized duodenal cancers have more complicated surgical resection considerations.
Adenocarcinoma and neuroendocrine carcinoma. Yes critical to know the difference as these two tumors have very different biological behavior and prognosis.
No, it is not approved except for the subset of cancers that are deficient in mismatch repair (also called microsatellite instability high) or if the tumor mutation burden is greater than 10 mut/mb.